Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

USFDA grants Priority Review for new indication of finerenone for patients with common heart failure

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure

Philips and Medtronic partner to upskill 300+ clinicians in structural heart imaging in India

Bayer files for approval of finerenone in heart failure in Japan

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure

Akums launches dual action heartburn relief chewable tablet

This product is categorized as antacids, antiflatulents and anti-Ulcerants

USV launches Q rite tablets for treatment of rare aprhythmia in heart patients

Quinidine Sulphate helps manage rare irregular heartbeat conditions

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases

OMRON Healthcare India and AliveCor partner to improve heart healthcare in India

These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more

Medanta launches monthly talk show around cardiac care - 'Heart 2 Heart'

The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe